- Home
- Companies
- Regenerative Medical Solutions Inc. ...
- Products
- RMS - ILC Cell Therapy Candidate Kit
RMS - ILC Cell Therapy Candidate Kit
We are developing autologous and allogeneic versions of ILC cellular therapeutic. In the case of autologous ILC cellular therapeutic we will convert the diabetes patients own cells into iPSC cells followed by differentiation of the patient derived iPSC into ILC using our patented and proprietary technology. These patient cell derived ILCs will then be surgically transplanted into the patient’s body. Our allogeneic version of ILC cellular therapeutic is derived from human iPSC cell line manufactured using GMP process.
This GMP human iPSC cell line is differentiated into ILC’s using our technology and subsequently transplanted into the patient’s body. Both approaches have the potential to cure type 1 and type 2 diabetes, since the transplanted ILCs will begin to function like the pancreas, by physiologically regulating glucose and insulin levels in the patient’s blood. Both ILC cellular therapeutic candidates are in pre-clinical development being evaluated in the laboratory and in animal models. We are working towards a phase I clinical trial to assess the safety of our ILC cellular therapeutic candidate in patients with diabetes.